A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females in generally good health aged 18-80 years with acute low back pain are eligible for this study.
- Patients must have pain of moderate to severe intensity on the patient rating of pain intensity scale without analgesia.
- Oral and written language comprehension at a level sufficient to comply with the protocol and complete study-related materials.
- Must have signed and dated an REB-approved written Informed Consent form which was also signed and dated by the Investigator prior to study participation.
Exclusion Criteria:
Known history or symptoms suspicious of:
- Spinal fracture
- Cancer (i.e. constitutional symptoms such as recent unexplained chills or weight loss)
- Spinal infection (e.g. IV drug abuse, immunosuppression)
- Cauda equina syndrome
- Spina bifida
- Foot drop
- Spinal surgery within 1 year of study entry
- Body Mass Index (BMI) > 37
- Continuous chronic back pain
- More severe pain in a region other than the lower back
- Treatment of the back pain with non-pharmacological therapy (e.g. acupuncture chiropractic adjustment, Transcutaneous Electrical Nerve Stimulation, physiotherapy etc.) in the 3 weeks prior to study entry
- Use of any sedative hypnotics, topical preparations/medications and anaesthetics or muscle relaxants within 5 half-lives of the dose of study medication
- Use of any analgesic within 6 hours of the dose of study medication. In rare cases, if a patient is in moderate to severe pain despite having taken a short-acting analgesic and if at least 2 hours have passed since the dose of short-acting analgesic, the patient may be entered.
- A major illness, requiring hospitalisation during the 3 months before commencement of the screening period
- Unwillingness to stop taking pain medication other than the study medication
- Previous failure of treatment with tramadol or discontinuation of treatment with tramadol due to adverse events
- Treatment within the last 3 weeks with any of the following medications: monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds (e.g. cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake inhibitors (SSRIs); serotonin-norepinephrine reuptake inhibitors (SNRIs) or any other drug that reduces seizure threshold
- Treatment with another investigational agent within the last 30 days
- History of seizure disorder other than Infantile Febrile Seizures
- Previous or current opioid dependency
- Bowel disease causing malabsorption
- Pregnant or lactating women
- Known significant liver disease or symptoms of significant liver disease
- Known significant renal disease or symptoms of significant renal disease
- Current or past substance abuse or dependence, other than nicotine
- Allergy to tramadol or any structurally similar drugs (e.g. opiates)
- Any other condition that, in the opinion of the Investigators, would adversely affect the patient's ability to complete the study or its measures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tramadol Contramid® OAD 200mg
1 Tramadol Contramid® OAD 200mg tablet daily.
|
1 Tramadol Contramid® OAD 200mg tablet daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Onset of Perceptible Pain Relief
Time Frame: 6 hours
|
Kaplan-Meier estimates of time to perceptible pain relief.
Patients who discontinued or completed the study without perceptible pain relief were censored at the time point of their last pain intensity score.
A confidence interval for the median survival time was calculated.
|
6 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Rating of Pain Intensity at Onset of Perceptible Pain Relief, 3 Hours and 6 Hours Post Dose
Time Frame: Baseline, 3 hours post-dose, 6 hours post-dose, time of onset of perceptible pain relief
|
Pain intensity rating at baseline, time of onset of perceptible pain relief, 3 hours and 6 hours post-dose or if the patient discontinued earlier.
"What is your current level of pain intensity?"
0=none, 1=mild, 2=moderate, 3=severe.
Missing data were imputed using Last Observation Carried Forward (LOCF).
|
Baseline, 3 hours post-dose, 6 hours post-dose, time of onset of perceptible pain relief
|
|
Patient Rating of Pain Relief at Onset of Perceptible Pain Relief, 3 Hours and 6 Hours Post Dose
Time Frame: 3 hours post-dose, 6 hours post-dose, at time of onset of perceptible pain relief
|
Pain relief rating at time of onset of perceptible pain relief, 3 hours and 6 hours post-dose or if the patient discontinued earlier.
" How would you rate the pain relief the study medication has given you?" ranging from 0=none to 4=complete relief.
Missing data were imputed using Last Observation Carried Forward (LOCF).
|
3 hours post-dose, 6 hours post-dose, at time of onset of perceptible pain relief
|
|
Plasma Levels of Tramadol at 0 Hour (Baseline), Onset of Perceptible Pain Relief, 3 Hours and 6 Hours Post-dose
Time Frame: Baseline, time of onset of perceptible pain relief, 3 hours post-dose, 6 hours post-dose
|
PK samples were drawn at the end of the Screening Phase, at the onset of perceptible pain relief, at 3 hours and at 6 hours post-dose or if the patient discontinues early.
PK samples were always drawn after the completion of the patient ratings of pain relief and of pain intensity scales.
They were processed in a central laboratory and the plasma levels of tramadol were collected.
|
Baseline, time of onset of perceptible pain relief, 3 hours post-dose, 6 hours post-dose
|
|
Number of Participants With Adverse Events
Time Frame: 6 hours
|
All adverse events reported during treatment with study drug were considered and reported as treatment emergent adverse events (TEAE) whether or not medication for this adverse event was required by the participant and were summarized in the same table.
|
6 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MDT2-002
- NCT00952068 (Registry Identifier: Clinicaltrials.gov)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.